TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Orphan drug designation granted to PCLX-001 by the FDA

By Dylan Barrett

Share:

Oct 18, 2022

Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.


On October 14, 2022, PCLX-001, a first-in-class, oral, small-molecule N-myristoylation inhibitor currently in clinical development, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia (AML).1

PCLX-001 has shown positive results in animal models of AML and in AML patient-derived xenografts, where PCLX-001 treatment reduced human peripheral blood and bone marrow CD45+ cells by up to 95%.1

PCLX-001 is currently being evaluated in a phase I trial in patients with non-Hodgkin lymphoma and solid tumors in Canada (NCT04836195). An investigational new drug application has been filed to study PCLX-001 in patients with AML in the United States.1

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?